scholarly journals Development and validation of a risk-prediction nomogram for chronic low back pain using a national health examination survey

2019 ◽  
Author(s):  
Jiwon Park ◽  
Jung-Taek Kim ◽  
Sang-Min Park ◽  
Ohsang Kwon ◽  
Hyoungmin Kim ◽  
...  

Abstract Background Several prognostic factors for chronic low back pain (CLBP) have been reported. However, there is no study regarding the prediction of CLBP development in general population, using a risk prediction model. Based on this background, the aims of this study were: (1) to develop and validate a risk prediction model for CLBP (chronic low back pain) development in the general population, and (2) to create a nomogram which can help a person at risk of developing CLBP to receive appropriate counseling on risk modification.Methods Data on CLBP development, demographics, socioeconomic history, and comorbid health condition of participants were obtained through a nationally representative health examination and survey from 2007 to 2009. Prediction models for CLBP development were derived for health survey on a random sample of 80% of the data and were validated in the remaining 20%. After developing the risk prediction model for CLBP development, this model was incorporated into a nomogram.Results Data for 17,038 participants were finally analyzed, including 2,693 with CLBP and 14,345 without. The finally selected risk factors included age, gender, occupation, education level, mid-intensity physical activity, depressive symptom, and comorbidities. This model had good predictive performance in the validation dataset (concordance statistic = 0.7569, Hosmer-Lemeshow chi-square statistic = 12.10, p =.278). The findings indicated no significant differences between the observed probability and predicted probability according to our model.Conclusions The risk prediction model, presented by a nomogram, which is a score-based prediction system, could be incorporated into the clinical setting. Thus, our prediction model with a nomogram can help a person at risk of developing CLBP to receive appropriate counseling on risk modification from primary physicians.

2003 ◽  
Vol 11 (1) ◽  
pp. 31-38 ◽  
Author(s):  
Olle Hägg ◽  
Carol Burckhardt ◽  
Peter Fritzell ◽  
Anders Nordwall

2018 ◽  
Vol 4 (2) ◽  
pp. 87 ◽  
Author(s):  
Gary J. Vorsanger, PhD, MD ◽  
Jim Xiang, PhD ◽  
Theophilus J. Gana, MD, PhD ◽  
Maria Luz G. Pascual, MD, MPH ◽  
R. Rosanna B. Fleming, MS

Background: This study evaluated the safety and efficacy of tramadol ER 300 mg and 200 mg versus placebo once daily in the treatment of chronic low back pain, using an open-label run-in followed by, without washout, a randomized controlled study design.Methods: Adults with scores ≥40 on a pain intensity visual analog scale (VAS; 0 = no pain; 100 = extreme pain) received open-label tramadol ER, initiated at 100 mg once daily and titrated to 300 mg once daily during a three-week open-label run-in. Patients completing run-in were randomized to receive tramadol ER 300 mg, 200 mg, or placebo once daily for 12 weeks.Results: Of 619 patients enrolled, 233 (38 percent) withdrew from the run-in, primarily because of adverse event (n = 128) or lack of efficacy (n = 41). A total of 386 patients were then randomized to receive either 300 mg (n = 128), 200 mg (n = 129), or placebo (n = 129). Following randomization, mean scores for pain intensity VAS since the previous visit, averaged over the 12-week study period, increased more in the placebo group (12.2 mm) than in the tramadol ER 300-mg (5.2 mm, p = 0.009) and 200-mg (7.8 mm, p = 0.052) groups. Secondary efficacy scores for current pain intensity VAS, patient global assessment, Roland Disability Index, and overall sleep quality improved significantly (p ≤ 0.029 each) in the tramadol ER groups compared with placebo. The most common adverse events during the double-blind period were nausea, constipation, headache, dizziness, insomnia, and diarrhea.Conclusions: In patients who tolerated and obtained pain relief from tramadol ER, continuation of tramadol ER treatment for 12 weeks maintained pain relief more effectively than placebo. Adverse events were similar to those previously reported for tramadol ER.


Spine ◽  
2012 ◽  
Vol 37 (9) ◽  
pp. 788-796 ◽  
Author(s):  
Sandra H. van Oostrom ◽  
Monique Verschuren ◽  
Henrica C. W. de Vet ◽  
Hendriek C. Boshuizen ◽  
H. Susan J. Picavet

Sign in / Sign up

Export Citation Format

Share Document